Trial 10M-24-2


NCI 10614 / PhII-239: A Phase 1/2 Study of Nivolumab and Ipilimumab in Combination with Sirolimus and Prednisone in Kidney Transplant Recipients with Selected Unresectable or Metastatic Cutaneous Cancers

Type: Treatment
Phase: Phase I/II
Status: Open to Accrual
Treatments: Biological Response Modifier, Chemotherapy: Systemic, Immunotherapy
Randomized: No
USC Satellite Location: USC Koreatown
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.
Other Trial Staff:  Mary Ordaz, D.M., Aida Lozada, Coordinator, Niranjan Bhatt, D.M., Sreebharathy Venkatesh, D.M., Sana Mutalib, Coordinator, Andrew Zeng, Coordinator, Thomas Won, Coordinator, Bomi Choi, Coordinator, Marie-Laure Gollier, D.M., Sophia Marmolejo, Coordinator, Sandy Tran, Coordinator, Azucena Vera, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.